Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publication
Artículo científico (JournalArticle)
Effect of polygenic risk score, family load of schizophrenia and exposome risk score, and their interactions, on the long-term outcome of first-episode psychosis
Background. Consistent evidence supports the involvement of genetic and environmental factors, and their interactions, in the etiology of psychosis. First-episode psychosis (FEP) comprises a group of disorders that show great clinical and long-term outcome heterogeneity,
and the extent to which genetic, familial and environmental factors account for predicting
the long-term outcome in FEP patients remains scarcely known.
Methods. The SEGPEPs is an inception cohort study of 243 first-admission patients with FEP
who were followed-up for a mean of 20.9 years. FEP patients were thoroughly evaluated by
standardized instruments, with 164 patients providing DNA. Aggregate scores estimated in
large populations for polygenic risk score (PRS-Sz), exposome risk score (ERS-Sz) and familial
load score for schizophrenia (FLS-Sz) were ascertained. Long-term functioning was assessed
by means of the Social and Occupational Functioning Assessment Scale (SOFAS). The relative
excess risk due to interaction (RERI) was used as a standard method to estimate the effect of
interaction of risk factors.
Results. Our results showed that a high FLS-Sz gave greater explanatory capacity for longterm outcome, followed by the ERS-Sz and then the PRS-Sz. The PRS-Sz did not discriminate
significantly between recovered and non-recovered FEP patients in the long term. No significant interaction between the PRS-Sz, ERS-Sz or FLS-Sz regarding the long-term functioning
of FEP patients was found.
Conclusions. Our results support an additive model of familial antecedents of schizophrenia,
environmental risk factors and polygenic risk factors as contributors to a poor long-term
functional outcome for FEP patients., This work was supported by the Government of Navarra (grants 17/31 and 18/41) and by the Carlos III Health Institute (FEDER Funds) from the Spanish Ministry of Economy and Competitivity (16/2148 and 19/1698).